Fig. 5: LiSmore enhances anti-PD-L1 treatment efficacy in an immunosuppressive LL/2 lung carcinoma model. | Nature Communications

Fig. 5: LiSmore enhances anti-PD-L1 treatment efficacy in an immunosuppressive LL/2 lung carcinoma model.

From: Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy

Fig. 5

a Schematic illustrating the in vivo LL/2 tumor model setup. 1 × 106 LL/2-OVAp lung carcinoma cells were injected (s.c.) in the flank of CD45.1 mice (n = 4 mice/group). Mice were transferred with OVAp-loaded BMDCs expressing Control or LiSmore at day 4, followed by adoptive transfer of CD45.2+ OT-1 CD8+ T cells. Anti–PD-L1 was administered (200 μg/mouse; i.p.) twice on days 8 and 11 after T cell transfer, using an isotype antibody as the control. Mice were subjected to pulsed blue light stimulation (470 nm at a power density of 2 mW/cm2; 30 min ON + 30 min OFF; 6 h per day) or kept without light stimulation (dark). b Images of isolated tumors at day 18 for each group. c LL/2 tumor volumes in the indicated groups of mice (n  =  4 per group; mean ± SD). Two-sided unpaired Student’s t-test. d Quantification of tumor weights at day 18. n = 4 mice (mean ± SD). One-way ANOVA.

Back to article page